Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand,
Drugs. 2015 Feb;75(2):207-17. doi: 10.1007/s40265-014-0344-z.
Silodosin is a highly selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms (LUTS) associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials. Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. The efficacy of silodosin was maintained in 9-month extension studies and was also seen in a phase IV study conducted in a real-world setting. Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. Abnormal ejaculation was the most commonly reported adverse event, although few patients discontinued treatment with silodosin because of this adverse event. In conclusion, silodosin is a useful option for the treatment of LUTS associated with BPH.
西洛多辛是一种高度选择性的α1A-肾上腺素受体拮抗剂，用于治疗良性前列腺增生（BPH）的症状和体征。在有下尿路症状（LUTS）相关 BPH 的男性中，西洛多辛具有快速起效的作用，在 12 周的精心设计的试验中，排尿和储存症状、最大尿流率和与健康相关的生活质量得到了改善。西洛多辛在改善与 BPH 相关的 LUTS 方面不劣于坦索罗辛。西洛多辛的疗效在 9 个月的扩展研究中得到维持，在一项真实环境下进行的 IV 期研究中也得到了证实。西洛多辛总体上耐受性良好，体位性低血压的风险较低。异常射精是最常报告的不良事件，尽管很少有患者因该不良事件停止使用西洛多辛。总之，西洛多辛是治疗与 BPH 相关的 LUTS 的一种有效选择。
